Glucagon, Glucagon-like Peptide (e.g., Glp-1, Glp-2, Etc.) Or Derivative Patents (Class 514/11.7)
-
Publication number: 20130209393Abstract: Therapeutic peptide compositions comprise a therapeutic peptide, such as insulin, together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate.Type: ApplicationFiled: May 4, 2011Publication date: August 15, 2013Applicant: NEXMED HOLDINGS, INC.Inventors: Bassam B. Damaj, Richard Martin
-
Publication number: 20130210721Abstract: [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventor: MOCHIDA PHARMACEUTICAL CO., LTD.
-
Publication number: 20130203673Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: ApplicationFiled: March 11, 2013Publication date: August 8, 2013Applicants: 1149336 Ontario, Inc., NPS Pharmaceuticals, Inc.Inventors: NPS Pharmaceuticals, Inc., 1149336 Ontario, Inc.
-
Publication number: 20130203659Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: ApplicationFiled: October 15, 2012Publication date: August 8, 2013Inventors: Leslie P. MIRANDA, Katherine Ann WINTERS, Murielle VENIANT-ELLISON
-
Publication number: 20130203660Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: ApplicationFiled: January 9, 2013Publication date: August 8, 2013Applicant: Indiana University Research and Technology CorporationInventor: Indiana University Research and Technology Corporation
-
Publication number: 20130203672Abstract: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.Type: ApplicationFiled: May 17, 2010Publication date: August 8, 2013Inventors: Shaojing Hu, Fenlai Tan, Yanping Wang, Cunbo Ma, Yunyan Hu, Hong Cao, Xiangdong Zhao, Wei Long, Yinxiang Wang, Lieming Ding
-
Patent number: 8501693Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.Type: GrantFiled: August 6, 2007Date of Patent: August 6, 2013Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Dennis Kim, Michael Trautmann
-
Publication number: 20130196906Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.Type: ApplicationFiled: January 29, 2013Publication date: August 1, 2013Applicant: CERULEAN PHARMA INC.Inventor: Cerulean Pharma Inc.
-
Publication number: 20130196898Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.Type: ApplicationFiled: November 26, 2010Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
-
Patent number: 8497240Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: GrantFiled: August 17, 2007Date of Patent: July 30, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
-
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
Publication number: 20130184204Abstract: The present invention relates to substituted quinazolines of formula (I): wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Type: ApplicationFiled: July 13, 2012Publication date: July 18, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Waldemar PFRENGLE, Markus FRANK, Thomas KLEIN -
Publication number: 20130184203Abstract: The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.Type: ApplicationFiled: July 27, 2011Publication date: July 18, 2013Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Josue Alfaro-Lopez, Abhinandini Sharma, Christopher J. Soares, Eugene Coats, Soumitra S. Ghosh
-
Patent number: 8486890Abstract: The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.Type: GrantFiled: March 15, 2007Date of Patent: July 16, 2013Assignee: Novo Nordisk A/SInventors: Thomas Kruse Hansen, Lauge Schäffer, Jesper Lau
-
Publication number: 20130178420Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.Type: ApplicationFiled: December 12, 2012Publication date: July 11, 2013Applicant: RECEPTOS, INC.Inventor: RECEPTOS, INC.
-
Patent number: 8481490Abstract: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.Type: GrantFiled: August 6, 2012Date of Patent: July 9, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Krystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin
-
Publication number: 20130172248Abstract: The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3 and R4 are each defined as specified, and to physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.Type: ApplicationFiled: January 4, 2013Publication date: July 4, 2013Inventors: Elisabeth DEFOSSA, Viktoria DIETRICH, Thomas KLABUNDE, Stefanie KEIL, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Johanna KUHLMANN-GOTTKE, Stefan BARTOSCHEK, Simon GESSLER, Angela DUDDA, Guenter BILLEN, Thomas OLPP, Joerg RIEKE-ZAPP
-
Publication number: 20130172244Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the subcutaneous or transdermal administration of a therapeutically effective amount of a certain DPP-4 inhibitor. The invention further relates to a subcutaneous combination of a certain DPP-4 inhibitor and GLP-1 having a short half life, particularly for reducing weight.Type: ApplicationFiled: December 27, 2012Publication date: July 4, 2013Inventors: Thomas KLEIN, Michael MARK
-
Publication number: 20130172243Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.Type: ApplicationFiled: December 7, 2012Publication date: July 4, 2013Applicant: Amylin Pharmaceuticals, LLCInventor: Amylin Pharmaceuticals, LLC
-
Publication number: 20130172249Abstract: The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor.Type: ApplicationFiled: September 9, 2011Publication date: July 4, 2013Applicant: ADVINUS THERAPEUTICS PRIVATE LIMITEDInventors: Dinesh Barawkar, Sujay Basu, Vidya Ramdas, Venkata Poornapragnacharyulu Palle, Yogesh Waman, Meena Patel, Anil Panmand
-
Publication number: 20130172257Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: ApplicationFiled: June 29, 2012Publication date: July 4, 2013Applicant: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 8476230Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.Type: GrantFiled: January 4, 2008Date of Patent: July 2, 2013Assignee: Hanmi Science Co., LtdInventors: Dae Hae Song, Chang Ki Lim, Tae Hun Song, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee, Sung Youb Jung, In Young Choi
-
Publication number: 20130165373Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: ApplicationFiled: June 29, 2012Publication date: June 27, 2013Applicant: Rani Therapeutics, LLCInventor: Mir Imran
-
Publication number: 20130165379Abstract: Provided herein are formulations containing exendins, exendin, agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion.Type: ApplicationFiled: November 8, 2012Publication date: June 27, 2013Applicant: Amylin Pharmaceuticals, LLCInventor: Amylin Pharmaceuticals, LLC
-
Publication number: 20130157934Abstract: Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.Type: ApplicationFiled: November 16, 2012Publication date: June 20, 2013Applicant: Indiana University Research and Technology CorporationInventor: Indiana University Research and Technology Corp
-
Publication number: 20130157935Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 23, 2011Publication date: June 20, 2013Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
-
Publication number: 20130157929Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.Type: ApplicationFiled: June 24, 2011Publication date: June 20, 2013Applicant: ZEALAND PHARMA A/SInventors: Ditte Riber, Eddi Meier
-
Publication number: 20130157953Abstract: The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.Type: ApplicationFiled: January 20, 2011Publication date: June 20, 2013Applicant: Zealand Pharma A/SInventors: Jørgen Søberg Petersen, Anne Louise Kjoelbye, Marie Skovgaard, Henrik Duelund Pedersen, Lene Axelsen, Ditte Riber, Eddi Meier, Rie Schultz Hansen, Keld Fosgerau, Bjarne Due Larsen
-
Publication number: 20130157942Abstract: The present invention provides stably cross-linked insulionotropic polypeptides having superior and un-expected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for pre-paring and evaluating the polypeptides of the invention.Type: ApplicationFiled: July 8, 2011Publication date: June 20, 2013Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Publication number: 20130157954Abstract: Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs.Type: ApplicationFiled: May 11, 2011Publication date: June 20, 2013Applicant: NPS PHARMACEUTICALS, INC.Inventors: Bo Joelsson, Henry H. Chu
-
Publication number: 20130157939Abstract: The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.Type: ApplicationFiled: August 18, 2011Publication date: June 20, 2013Inventor: Shmuel Ben-Sasson
-
Publication number: 20130157941Abstract: The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances.Type: ApplicationFiled: June 17, 2011Publication date: June 20, 2013Applicant: SanofiInventors: Stefan Petry, Norbert Tennagels, Karl-Heinz Baringhaus
-
Publication number: 20130150296Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: April 1, 2011Publication date: June 13, 2013Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20130143798Abstract: The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: March 28, 2011Publication date: June 6, 2013Applicant: NOVO NORDISK A/SInventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen
-
Publication number: 20130137629Abstract: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula I or a pharmaceutically acceptable salt thereof Three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and m is 0, 2 or 4. R6 is hydrogen, O or hydroxy, and X is —OR7, wherein R7 is hydrogen or alkyl having from 1 to 3 carbon atoms; or R6 is hydrogen, and X is —NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl. When X is —NR8R9, hydroxy none of R1, R2, R3, R4 and R5 is hydroxy.Type: ApplicationFiled: January 24, 2013Publication date: May 30, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventor: WELLSTAT THERAPEUTICS CORPORATION
-
Patent number: 8450270Abstract: Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.Type: GrantFiled: June 16, 2009Date of Patent: May 28, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, David L. Smiley, Maria Dimarchi, Joseph Chabenne, Jonathan Day
-
Publication number: 20130130974Abstract: The present invention relates to process to prepare ?-aminobutyryl compounds having ?-amino acid core structural moieties and optionally having ?-phenyl and/or heterocyclic structural moieties. Such compounds are useful as key structure framework of modern drug chemistry.Type: ApplicationFiled: June 3, 2011Publication date: May 23, 2013Inventors: Damjan Sterk, Matjaz Ustar, Marko Zlicar
-
Publication number: 20130118491Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.Type: ApplicationFiled: January 9, 2013Publication date: May 16, 2013Applicant: MannKind CorporationInventor: MannKind Corporation
-
Publication number: 20130123178Abstract: Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.Type: ApplicationFiled: May 10, 2011Publication date: May 16, 2013Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Richard D. DiMarchi, Bin Yang, Brian Finan
-
Publication number: 20130116179Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.Type: ApplicationFiled: September 4, 2012Publication date: May 9, 2013Applicants: UNIVERSITY OF ULSTER, SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN
-
Publication number: 20130116172Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.Type: ApplicationFiled: May 10, 2011Publication date: May 9, 2013Applicant: MARCADIA BIOTECH, INC.Inventors: Richard D. Dimarchi, Lianshan Zhang
-
Publication number: 20130116173Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.Type: ApplicationFiled: December 27, 2012Publication date: May 9, 2013Applicant: Indiana University Research and Technology CorporationInventor: Indiana University Research and Technology Corporation
-
Publication number: 20130096056Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where V, W, R1, R2, R3 and R4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.Type: ApplicationFiled: September 14, 2012Publication date: April 18, 2013Applicant: XENON PHARMACEUTICALS INC.Inventors: Jianmin Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Serguei Sviridov, Zaihui Zhang
-
Publication number: 20130095037Abstract: In the current invention peptides, which are derived from GLP-1 (glucagon-like peptide-1) and exendin-3 and/or exendin-4, are provided which bond to the GLP-1 receptor and can be used, labeled or unlabeled, for the production of an agent for diagnostic and therapy of benign and malignant diseases, in which GLP-1 receptor expression plays a role.Type: ApplicationFiled: August 24, 2012Publication date: April 18, 2013Applicant: Philipps-Universitat MarburgInventors: Martin GOTTHARDT, Martin Béhé, Thomas Behr, Burkhard J. Göke
-
Publication number: 20130096059Abstract: The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated (a) stenosis or/and obstruction located in the biliary tract, or/and (b) biliary dyskinesia, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.Type: ApplicationFiled: October 2, 2012Publication date: April 18, 2013Inventors: Jens STECHL, Irene NOWOTNY, Claudia PFEIFFER, Jean-Louis PINQUIER, Jerome MSIHID
-
Publication number: 20130096060Abstract: The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated with stenosis or/and obstruction located in the pancreatic duct system, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.Type: ApplicationFiled: October 2, 2012Publication date: April 18, 2013Inventors: Jens STECHL, Irene NOWOTNY, Claudia PFEIFFER, Jean-Louis PINQUIER, Jerome MSIHID
-
Publication number: 20130090287Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.Type: ApplicationFiled: November 29, 2012Publication date: April 11, 2013Applicant: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang
-
Publication number: 20130090286Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: ApplicationFiled: August 6, 2012Publication date: April 11, 2013Inventors: Elisabetta Bianchi, Antonello Pessi, Jonathan Day, Richard Dimarchi, David Smiley
-
Publication number: 20130089545Abstract: The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity.Type: ApplicationFiled: September 22, 2011Publication date: April 11, 2013Inventor: Stephen Robert Bloom
-
Publication number: 20130084277Abstract: The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.Type: ApplicationFiled: August 24, 2012Publication date: April 4, 2013Applicant: PhaseBio Pharmaceuticals, Inc.Inventors: Susan Arnold, Christopher Prior
-
Publication number: 20130079278Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: September 21, 2012Publication date: March 28, 2013Applicant: NOVO NORDISK A/SInventor: Novo Nordisk A/S